5 Nuts To Improve Cardiovascular Health
The health of your heart is directly influenced by what you eat. Among the many heart-friendly foods, nuts stand out as nutritional powerhouses packed with healthy fats, fibre, antioxidants, and essential minerals. Several studies have shown that regular consumption of certain nuts can significantly lower LDL (bad) cholesterol, reduce inflammation, and improve overall heart function. According to the American Heart Association (AHA), including a small handful of unsalted, unroasted nuts in your daily diet can support heart health and reduce the risk of cardiovascular diseases. Let's explore five nuts that can help keep your heart strong and your arteries clear.
How nuts improve heart health
Nuts are rich in unsaturated fats, plant sterols, omega-3 fatty acids, magnesium, and L-arginine, all known to support cardiovascular well-being. They help lower blood pressure, improve lipid profiles, and reduce plaque formation in arteries. The World Health Organisation (WHO) also recognises the role of nuts in preventing heart disease when consumed as part of a balanced, plant-based diet. Here are five nuts to boost your cardiovascular health.
1. Almonds
Almonds are packed with vitamin E, magnesium, and mono-unsaturated fats. They help lower LDL cholesterol and support arterial function. A study published in the Journal of the American Dietetic Association found that incorporating almonds into a low-fat diet significantly improved cholesterol levels and reduced the risk of coronary heart disease.
2. Walnuts
Walnuts are one of the richest plant-based sources of omega-3 fatty acids, particularly alpha-linolenic acid (ALA). The American Heart Association notes that omega-3s play a crucial role in reducing inflammation, stabilising heart rhythms, and lowering triglycerides. Eating a small serving of walnuts daily can also help maintain healthy blood pressure.
3. Pistachios
These green-hued nuts are high in potassium, fibre, and antioxidants like lutein. Pistachios have been shown to lower total and LDL cholesterol while improving HDL (good) cholesterol. A clinical trial published in Hypertension found that pistachio consumption helped reduce systolic blood pressure in adults with high cholesterol.
4. Hazelnuts
Hazelnuts contain heart-friendly fats, vitamin E, and phytosterols. Regular consumption may improve blood vessel elasticity and reduce oxidative stress. A study in Nutrition, Metabolism & Cardiovascular Diseases concluded that hazelnuts can improve lipid profiles and support vascular health when consumed in moderation as part of a Mediterranean-style diet.
5. Brazil nuts
These large, creamy nuts are exceptionally rich in selenium, a mineral known for its antioxidant properties and role in reducing inflammation. Selenium also helps improve blood vessel function. According to the National Institutes of Health (NIH), just one or two Brazil nuts a day may meet your daily selenium needs and support heart health.
Adding a small serving of heart-healthy nuts to your daily diet can be a simple yet powerful step towards better cardiovascular health. Just remember, moderation is key, as nuts are calorie-dense. Opt for unsalted, unflavoured varieties for maximum benefit. With guidance from a nutritionist or healthcare provider, these superfoods can become your heart's best ally for the long run.
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. NDTV does not claim responsibility for this information.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
8 hours ago
- Business Standard
Bharat Biotech signs pact with GSK to develop Shigella vaccine candidate
Bharat Biotech on Thursday announced its partnership with UK-based pharma company GSK for the development and potential use of the Shigella vaccine candidate altSonflex1-2-3. As part of the agreement, Bharat Biotech will lead the further development of altSonflex1-2-3, including Phase 3 clinical trials, regulatory advancement and large-scale manufacturing. GSK, on the other hand, will support the programme by assisting with clinical trial design, securing external funding and contributing to the access and delivery plans and commercialisation strategy. The company said that the agreement marks a significant step in advancing the vaccine, which targets shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five years of age in low- and middle-income countries (LMICs). 'The vaccine candidate has already demonstrated a strong safety and immunogenicity profile in both European and African trials, including in the primary target population of nine-month-old infants,' it added. Commenting on the development, Krishna Ella, Executive Chairman at Bharat Biotech, said that with no approved vaccine currently available and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on LMICs. 'This collaboration combines our strengths in innovation, manufacturing and global health commitment.' According to the World Health Organisation (WHO), Shigella was the second-leading cause of diarrhoeal mortality in 2016 (latest data) among all ages and the leading bacterial cause of diarrhoea, accounting for approximately 212,000 deaths and about 13 per cent of all diarrhoea-associated deaths. The disease is a major contributor to child morbidity and mortality, and the emergence of drug-resistant strains underscores the urgent need for a preventive vaccine. The standard of care for shigellosis primarily involves managing dehydration and using antibiotics. While mild cases often resolve with rest and fluid replacement, more severe cases or those with weakened immune systems may benefit from antibiotics like ciprofloxacin or azithromycin. Thomas Breuer, Chief Global Health Officer at GSK, said that by helping reduce illness and antibiotic use, this vaccine has the potential to play a critical role in combating antimicrobial resistance (AMR). The companies claimed that the vaccine candidate has broad serotype coverage, an innovative Generalised Modules for Membrane Antigens (GMMA)-based platform and robust early clinical results. 'GMMA technology is a platform that uses bacterial outer membranes to deliver the O antigen to the immune system, allowing for high-yield production, which creates affordable vaccines for underserved populations,' they added in a statement.
United News of India
15 hours ago
- United News of India
India reports 7,151 active Covid-19 cases; six new deaths in last 24 hrs
New Delhi, June 12 (UNI) India's total number of Covid-19 cases has reached 7,151 as of 8 AM on Thursday, according to the Ministry of Health and Family Welfare. In the past 24 hours, 33 new infections have been confirmed, though case data from West Bengal is still awaited. Additionally, six new deaths linked to Covid-19 were reported in the last 24 hours: three from Kerala, two from Karnataka, and one from Maharashtra. These bring the total number of Covid-related deaths in 2025 to 74. On a positive note, more than 8,000 individuals have recovered from the virus so far this year. While several states have reported modest increases in active cases, Kerala remains the worst affected, with 2,223 active infections as of Thursday. Other states with relatively high caseloads include Gujarat, West Bengal, Delhi, and Maharashtra, based on data from the national COVID-19 dashboard. Health authorities attribute the current rise in infections to new Omicron sub-variants including JN.1, NB.1.8.1, LF.7, and XFC. These strains are noted for their high transmissibility but are causing milder illness compared to earlier variants. The World Health Organisation (WHO) has classified them as "Variants Under Monitoring", indicating that while they are not currently a serious threat, their progress should be observed closely. Covid-19, caused by the SARS-CoV-2 virus, has now transitioned into a seasonal pattern similar to the flu. Though no longer considered an emergency, the virus continues to circulate and may pose risks, especially to vulnerable populations. UNI AJ ARN
Hindustan Times
17 hours ago
- Hindustan Times
New Covid-19 variant causes sore throat that feels like 'razor blades': Everything to know about NB.1.8.1 aka Nimbus
The variant, NB.1.8.1, has been informally dubbed 'Nimbus' and causes a severe sore throat that's been likened to 'razor blades'. The World Health Organisation (WHO) is monitoring it, as this latest mutation of the contagious virus already makes up over 10 percent of cases in Asia, Salon said in a June 11 report. The portal added that NB.1.8.1 has now been detected in multiple countries, including the US and Canada. Also read | Covid-19 comeback: Here's why coronavirus is spreading again and new symptoms you should watch out for The Covid-19 variant NB.1.8.1, also known as Nimbus, is a descendant of the Omicron family and has been classified as a Variant Under Monitoring (VUM) by the WHO. To mitigate the spread of NB. 1.8.1, it's essential to practice good respiratory hygiene, maintain social distancing, and follow public health guidelines. Salon reported that this strain causes 'razor blade throat' or a severe sore throat. Other symptoms include flu-like symptoms such as congestion, fatigue, a mild cough, fever, and muscle aches, and more infrequently diarrhoea and nausea, The Independent said in a June 10 report. Per that portal, WHO says global risk is 'currently low, and existing Covid-19 vaccines are considered effective in preventing severe disease'. Salon said that Nimbus has recombined genetic material from other strains three times – although the process of recombination is a natural process of viruses trying to evolve to survive among the population, recombination events are concerning because each time a virus does so, it has the potential to evolve into something that is more infectious or causes more severe disease. The portal quoted Dr Rajendram Rajnarayanan of the New York Institute of Technology campus in Jonesboro, Arkansas, as having said that one of these mutations in Nimbus allows it to evade the immunity we have built against the virus from prior infections, so transmissibility might be slightly higher. Dr Rajnarayanan also said: 'We haven't seen a big surge in emergency departments due to Covid-related conditions and respiratory things in this term yet. We have to wait and watch.' Dr T Ryan Gregory, an evolutionary and genome biologist at the University of Guelph in Canada, added, 'We learned from Omicron that high transmissibility can cause as much damage as high per infection virulence, and at this point it is not just acute severity that is of concern, but longer-term impacts of repeated infection.' Such impacts include conditions like 'long Covid', in which the symptoms of Covid-19 last for months or years, often disabling patients, the report added. Note to readers: This article is for informational purposes only and not a substitute for professional medical advice. Always seek the advice of your doctor with any questions about a medical condition.
